Evidence map›Paper›PMID 26648979›Full record

ArticlePakistan journal of medical sciences

Current trends in treatment of hypertension in Karachi and cost minimization possibilities.

Izhar M Hussain, Baqir S Naqvi, Rao M Qasim, Nasir Ali

Open access · goldAbstract read
In one paragraph

Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Management of Hypertension in the Asia-Pacific Region: A Structured Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Izhar M HussainIzhar M. Hussain, M. Pharm., MBA. Director, Center for Executive Education, Institute of Business Administration, IBA City Campus, Garden / Kiyani Shaheed Road, Karachi, Pakistan.
Baqir S NaqviDr. Baqir S. Naqvi, PhD. Professor, Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.
Rao M QasimRao M. Qasim, Pharm. D, M. Phil., MBA Institute of Business Management, Karachi, Pakistan.
Nasir AliNasir Ali, MBA Supply Chain Management, Research Executive, IBA Center for Executive Education, Karachi, Pakistan.
American Pharmacists Association · USSitma (Norway) · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study finds out drug usage trends in Stage I Hypertensive Patients without any compelling indications in Karachi, deviations of current practices from evidence based antihypertensive therapeutic guidelines and looks for cost minimization opportunities.

methodsIn the present study conducted during June 2012 to August 2012, two sets were used. Randomized stratified independent surveys were conducted in doctors and general population - including patients, using pretested questionnaires. Sample sizes for doctors and general population were 100 and 400 respectively. Statistical analysis was conducted on Statistical Package for Social Science (SPSS). Financial impact was also analyzed.

resultsOn the basis of patients' doctors' feedback, Beta Blockers, and Angiotensin Converting Enzyme Inhibitors were used more frequently than other drugs. Thiazides and low-priced generics were hardly prescribed. Beta blockers were prescribed widely and considered cost effective. This trend increases cost by two to ten times.

conclusionFeedbacks showed that therapeutic guidelines were not followed by the doctors practicing in the community and hospitals in Karachi. Thiazide diuretics were hardly used. Beta blockers were widely prescribed. High priced market leaders or expensive branded generics were commonly prescribed. Therefore, there are great opportunities for cost minimization by using evidence-based clinically effective and safe medicines.

Indexed as

Compelling indicationsCost minimizationEvidence-based therapeutic guidelinesInitial therapyStage I hypertension

Identifiers

PMID26648979
PMCPMC4641248
OpenAlexW2195519022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.